Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
IONS submitted a Form 144 notice reporting proposed sales of Common Stock. The excerpt lists numeric entries 5,035,928.00 and 161,970,000 with an explicit date of 03/03/2026 and identifies the market as Nasdaq. The filing itemizes common stock tied to an Option Exercise (07/01/2018) and Restricted Stock Units (07/15/2021).
IONS filed a Form 144 reporting proposed sales of Common Stock by an affiliate. The filing lists securities tied to option exercises dated 01/02/2024, 01/03/2023, and 01/03/2022 with quantities 10,461, 4,145, and 5,500, and Restricted Stock Units dated 01/13/2024 totaling 15,937 shares.
The filing also discloses recent sales by Shannon Devers: 44,199 shares on 01/07/2026 ($3,756,915.00), 8,353 shares on 01/16/2026 ($636,626.00), and 3,977 shares on 01/22/2026 ($323,490.00).
Ionis Pharmaceuticals EVP Research Eric Swayze reported an employee stock purchase plan transaction in Ionis common stock. On February 27, 2026, he acquired 256 shares under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan at an average price of $48.8665 per share. These plan shares may not be sold until August 27, 2026. After this transaction, he directly held 32,361 common shares. A separate line also shows 318 shares held indirectly by his son.
Ionis Pharmaceuticals executive Patrick R. O'Neil acquired additional common shares through an employee stock purchase plan. On February 27, 2026, he purchased 376 shares of Ionis common stock at an average price of $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan. Following this transaction, his direct holdings increased to 72,359 common shares, and the newly purchased shares cannot be sold until August 27, 2026.
IONIS PHARMACEUTICALS INC CEO Brett P. Monia acquired 484 shares of common stock on February 27, 2026 through the company’s Amended and Restated 2000 Employee Stock Purchase Plan at $48.8665 per share. After this transaction, the CEO directly owns 254,981 shares. These shares may not be sold until August 27, 2026.
Ionis Pharmaceuticals executive Brian Birchler reported an employee stock purchase transaction. On February 27, 2026, he purchased 351 shares of Ionis common stock at an average price of $48.8665 per share under the company’s Amended and Restated 2000 Employee Stock Purchase Plan, bringing his direct holdings to 66,598 shares. These shares may not be sold until August 27, 2026.
Ionis Pharmaceuticals executive Frank Bennett, EVP and Chief Scientific Officer, reported a small personal share purchase through the company’s employee stock purchase plan. On February 27, 2026, he acquired 261 shares of Ionis common stock at $48.8665 per share under the Amended and Restated 2000 Employee Stock Purchase Plan.
Following this transaction, Bennett directly owns 100,554 common shares. According to the filing, these newly purchased shares are subject to a holding period and may not be sold until August 27, 2026, which temporarily restricts his ability to dispose of this specific block of stock.
Ionis Pharmaceuticals outlines its evolution into a fully integrated commercial-stage biotechnology company focused on RNA- and DNA-targeted medicines. The company now has seven marketed drugs, including TRYNGOLZA for familial chylomicronemia syndrome, DAWNZERA for hereditary angioedema, WAINUA for hereditary transthyretin amyloidosis, SPINRAZA for spinal muscular atrophy, QALSODY for SOD1-ALS, and TEGSEDI and WAYLIVRA for rare lipid and amyloid diseases.
Ionis is preparing two additional independent U.S. launches in 2026, assuming approval: olezarsen for severe hypertriglyceridemia (with FDA priority review and a PDUFA date of June 30, 2026) and zilganersen for Alexander disease, for which an NDA was submitted in January 2026. The company reported $944 million in revenue in 2025 and ended the year with $2.7 billion in cash, cash equivalents and short-term investments, supporting continued investment in its pipeline.
The business is underpinned by extensive global partnerships with AstraZeneca, Biogen, GSK, Novartis, Roche, Otsuka and others that provide royalties, milestones and shared development funding. Ionis also highlights a broad late- and mid-stage pipeline across neurology, cardiometabolic and rare diseases, and continued investment in next-generation technologies such as MsPA backbone chemistry, Bicycle- and Vect-Horus–enabled delivery and gene-editing collaborations.
Ionis Pharmaceuticals reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year revenue rose to $944 million from $705 million, driven by commercial growth and R&D collaboration revenue, including a $280 million upfront payment for sapablursen licensing.
TRYNGOLZA generated $108 million in 2025 net product sales in its first launch year, helping lift commercial revenue 49% year over year. Despite this growth, the company posted a 2025 GAAP net loss of $381 million and a non-GAAP operating loss of $248 million, both improved versus 2024.
Cash, cash equivalents and short-term investments increased to $2.7 billion as of December 31, 2025, aided by convertible debt refinancing. For 2026, Ionis guides to $800–$825 million in revenue, a non-GAAP operating loss of $500–$550 million, and year-end liquidity of about $1.6 billion, while continuing to invest in multiple independent launches and a broad late-stage pipeline.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 9,108,019 shares of Ionis Pharmaceuticals common stock, representing 5.6% of the outstanding class as of the event date.
The firm reports sole voting power over 9,083,319 shares and sole dispositive power over 9,108,019 shares, with no shared voting or dispositive authority. It certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Ionis Pharmaceuticals, and includes a legal disclaimer that it is not admitting beneficial ownership.